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Abstract
The past decade has been proclaimed as a hugely successful era of gene discovery through
the high yields of many genome-wide association studies (GWAS). However, much of the
perceived benefit of such discoveries lies in the promise that the identification of genes that
influence disease would directly translate into the identification of potential therapeutic tar-
gets, but this has yet to be realized at a level reflecting expectation. One reason for this, we
suggest, is that GWAS, to date, have generally not focused on phenotypes that directly
relate to the progression of disease and thus speak to disease treatment.
A valuable proposed outcome of the GWAS era is the identification of novel therapeutic tar-
gets [1–4]. As of 3 April 2017, the GWAS Catalog contained 2,854 publications and 33,674
unique SNP-trait associations [5]. The large majority of these studies investigate genetic varia-
tion related to the presence (or occurrence) of disease. Such variants, though they may be
informative for the prevention of disease, have unclear utility in informing disease treatment.
If variants implicate etiological mechanisms of import for disease onset but sometimes of little
relevance to disease progression, then the use of case/control GWAS as evidence to inform dis-
ease treatment–related drug discovery could be misleading. As an obvious example, consider
GWAS of lung cancer. The lead variants identified in such GWAS tag a locus related to the
heaviness of cigarette smoking [6], supporting the overwhelming evidence that smoking causes
lung cancer. However, the cessation of smoking is hardly an efficacious treatment strategy
after the onset of disease, although not smoking is a highly effective means of very substantially
reducing the risk of developing lung cancer in the first place. Examples of factors causing both
disease incidence and disease progression exist—for example, low-density lipoprotein (LDL)
cholesterol levels clearly influence the risk of initial coronary events, and lowering LDL choles-
terol reduces the risk of subsequent events. However, it is not necessarily the case that risk fac-
tors will influence both disease onset and disease progression—for example, a recent GWAS of
Crohn disease observed independent genetic variants for the risk of onset and progression [7]
and reported a negative genetic correlation (estimated through linkage disequilibrium [LD]
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score regression) between occurrence and progression, although this was imprecisely esti-
mated. It is indeed possible that, in some cases, the effects of a particular exposure on the initi-
ation and prognosis of disease could be in opposite directions, as has been suggested with
respect to folate intake and colon cancer [8].
Few heritability studies of disease progression have been conducted. But there is evidence
that disease progression phenotypes can have appreciable heritability (e.g., h2 = 74%–76% for
progression of lumbar disc degeneration [9] and high inter-sibling concordance for multiple
sclerosis progression [10]). In contrast to the large body of research on the genetic risk of dis-
ease incidence, only a small proportion of GWAS (approximately 8% of associations curated
in the GWAS Catalog [p< 1 x 10−5]) have attempted to identify variants associated with dis-
ease progression or severity, and those that have are mostly small (90% have n< 5,000). This is
most likely due to a research focus on mechanisms of the underlying causes of disease, as well
as the limitation of available disease progression data, partly because measures of progression
are harder to define and collect than more straightforward case/control phenotypes. But there
is clearly interest in the GWAS field to conduct studies of progression, and so we expect to see
an upward trend (in number and sample size) of such studies in the coming years, similar to
that already seen for GWAS of disease occurrence. Investigating disease progression as a trait
offers a considerable opportunity for identifying treatment targets and informing therapeutics,
but it also introduces several important complications that have had little formal discussion in
the literature and have not been addressed in many of the existing disease progression studies.
A key problem, which we will discuss in more detail, is the issue of the potential introduction
of collider bias when studying a selected (i.e., case-only) group of individuals.
GWAS are now routinely being used to help strengthen causal inference with respect to
observational associations between exposures and disease by using Mendelian randomization
(MR) (see Box 1) [11, 12]. With its emphasis on causality, it is important to appreciate that the
challenges we present here also apply to MR. To date, few studies have used MR to identify fac-
tors influencing disease progression. In S1 Table, we summarize the 28 MR studies of progres-
sion that we identified in a systematic search. Only 1 of these studies [13] acknowledged the
issue of the potential introduction of confounding through collider bias; interestingly, this was
the first of these studies to be published.
Challenges for genetic and MR studies of disease progression
Collider bias
Collider bias is a fundamental issue in progression studies [27]. Fig 2 shows an example causal
diagram (or directed acyclic graph [DAG]) depicting the causes of disease incidence and pro-
gression. In this DAG, disease incidence is a collider because the paths from the risk factor for
incidence (A) and the measured (C) and unmeasured (U) factors for both incidence and prog-
nosis (C/U) collide at the disease incidence variable—i.e., A and C/U both cause disease. A col-
lider blocks a path, so in this diagram, there is no path from A to C/U because the only path is
blocked by disease incidence (the collider). However, conditioning on a collider opens the
path (dashed line), which can then induce collider bias because there is then a noncausal path
from A to C/U and onwards to disease progression. Conditioning on the collider can occur by
stratifying on the variable or by adjusting for it in statistical analyses.
When a study group is selected on certain characteristics (e.g., being cases for a particular
disease), this can introduce associations between all independent risk factors for these charac-
teristics. For example, in a study of coronary heart disease (CHD) progression in which only
CHD cases are selected for inclusion, there will be associations induced between all CHD risk
factors (genetic and nongenetic) amongst the study individuals. Therefore, in a genetic study
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of progression within these cases, collider bias will induce spurious associations between
genetic variants and progression (provided that at least 1 other factor influences both inci-
dence and progression) [28]. Similarly, in an MR study of progression within these cases, the
assumption that “the genetic instrument is independent of factors that confound the associa-
tion of the exposure and the outcome” (assumption 2, Box 1) would be violated (see Box 2).
Selection on case status does not automatically lead to bias: the presence, magnitude, and
direction of the bias depend on the exact nature of the combined effects of the variables on dis-
ease status and the relationships between the variables.
Box 1. Mendelian randomization.
Mendelian randomization (MR) is an approach that uses genetic variation to improve
causal inference in observational studies. A genetic variant associated with the exposure
of interest (genetic instrument) is used to test the causal relationship between exposure
and outcome (Fig 1). If there is an association between the genetic instrument and the
outcome, then there is assumed to be a causal relationship because, unlike in the obser-
vational association, the genetic variant is not subject to issues of reverse causation and/
or confounding. Assumptions of MR include the following [14]:
1. The genetic instrument is associated with the exposure of interest.
2. The genetic instrument is independent of factors that confound the association of the
exposure and the outcome.
3. The genetic instrument is independent of the outcome, given the exposure and the
confounders.
The method has been widely applied in the investigation of exposures that increase
the risk of disease [15], both within single studies and in a 2-sample framework based on
summary data, generally from large-scale genome wide association study (GWAS) con-
sortia [16]. Such studies have demonstrated evidence of causal relationships (e.g., for
obesity, blood pressure, and smoking with an increased risk of coronary heart disease
[CHD] [17–19]), a lack of causal relationships (e.g., for C-reactive protein relationship
with CHD, diabetes, and cancer [20–22]), debunking supposed protective behaviors
(such as the beneficial effects of moderate alcohol intake on CHD risk [23]), and predict-
ing randomized controlled trial successes and failures [24].
The emphasis on causality in a MR study has led to the acknowledgment within the
field that they are also likely to have great value in suggesting what are likely to be suc-
cessful interventions for the treatment of disease [25,26]. However, there are particular
aspects of the study of disease prognosis that limit the applicability of MR.
Fig 1. DAG of Mendelian randomization method. Abbreviation: DAG, directed acyclic graph.
https://doi.org/10.1371/journal.pgen.1006944.g001
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We investigated the bias due to studying cases by only using a simple simulation study
(Table 1). We simulated the situation depicted in Fig 2 with both a measured (C) and an
unmeasured (U) confounder of disease incidence and progression. We simulated situations
with low, moderate, high, and strong confounding. Collider bias has somewhat different impli-
cations for 2 underlying biological mechanisms. There is 1 (as depicted in Fig 2) in which risk
factor A causes disease incidence, but A does not cause disease progression. In this scenario,
studying only cases introduces collider bias, which induces an association between A and C
and thus results in an induced association between A and disease progression in the study
sample (Table 1). The bias in the estimated effect of A on disease progression increases as the
degree of unmeasured confounding of disease incidence and progression increases (i.e., the
degree to which there are common factors that influence disease onset and progression), with
the proportion of 95% confidence intervals including the true effect of zero, falling from 90%
(low confounding) to 35% (strongest confounding). The second scenario is one in which risk
factor C causes both disease incidence and progression (Fig 2). Collider bias is again induced
by studying only cases, and here it biases the estimated effect of C on progression towards the
null (Table 1). Again, the bias increases as the degree of confounding of incidence and progres-
sion increases.
Fig 2. DAG demonstrating the issue of collider bias in studies with participants selected according to
disease status. In this situation, collider bias can induce an association (dashed line) between any factors (A,
C, and U) that affect disease incidence (or other study selection criteria). When 1 or more of these factors are
also associated with disease progression (C, U), a path is opened up from A to disease progression through
the induced association. If A is a genetic risk factor, it can appear that there is an association between genetic
risk factor A and disease progression only because of the induced association with C or U. If C is measured
and can be adjusted for, then the induced association is blocked, but unmeasured U cannot be adjusted for in
the analysis. Only when the genetic risk factor for progression is not also a risk factor for incidence (i.e., B) will
it not be affected by selection bias. The arrows in Figure 2 show causal paths between variables—e.g., that
variable A causes disease incidence. A collider is a variable which has 2 paths entering it, e.g., disease
incidence. A path is blocked by a collider—i.e., the path from A to disease progression is blocked by disease
incidence. If a collider is conditioned on, then that path is unblocked—i.e., if disease incidence is conditioned
upon, then the path from A to disease progression becomes unblocked (i.e., collider bias may occur).
Abbreviation: DAG, directed acyclic graph.
https://doi.org/10.1371/journal.pgen.1006944.g002
Box 2. Collider bias in Mendelian randomization.
Collider bias is an issue in Mendelian randomization (MR) of progression because, for
any exposure that causes the onset of disease, the genetic instruments for that exposure
may, amongst cases, be associated with other risk factors for onset, and so the association
between the genetic variant and progression may be subject to confounding by these fac-
tors (Fig 3). Although this is true for single variants, the combination of variants into a
polygenic score may serve to increase this effect [29].
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This collider bias can lead to either an over- or under-identification of genetic risk factors
for progression, depending on the direction of the relationships between the risk factors and
disease onset. Collider bias should always be properly considered, and a number of things can
be done to mitigate this potential bias.
1. Check for an association between the genetic variant and disease incidence in any study of
disease progression. When a variant is identified as being associated with progression, the
association between this variant and disease incidence (or other selection criteria) should
also be reported. This can indicate whether there is any potential for collider bias.
Table 1. Estimated effects of the risk factor for incidence only (A) and the risk factor for incidence and progression (C) from Fig 2 under different
degrees of unmeasured confounding of incidence and progression.
Degree of confounding by unmeasured confounder(s) (U)
Simulated scenario Low Moderate High Strong









Apparent effect of A on progression
(regression coefficient, SE)
True effect = 0
−0.01 (0.01) −0.02 (0.02) −0.03 (0.02) −0.06 (0.03)
Percentage of 95% CI including 0 90% 78% 66% 35%
Apparent effect of C on progression
(regression coefficient, SE)
True effect = 0.1
0.10 (0.01) 0.08 (0.01) 0.07 (0.01) 0.04 (0.02)
Proportion of 95% CI including 0.1 72% 35% 18% 1%
Each cell represents results from 500 simulations with a sample size of 50,000.
Uppercase letters refer to factors in Fig 2, lowercase letters refer to effect sizes of paths in Fig 2.
In all scenarios the OR for A and C for disease incidence are 1.3, and the MAF for genetic variants A is 0.2.
C and the U are standard normal variables, disease is a binary variable (with prevalence of approximately 0.2), and prognosis is a normally distributed
variable.
Abbreviations: A, risk factor for incidence; C, measured factor for incidence and progression; MAF, minor allele frequency; OR, odds ratio; SE, standard
error; U, unmeasured factor for incidence and progression.
https://doi.org/10.1371/journal.pgen.1006944.t001
Fig 3. DAG to demonstrate how the introduction of collider bias through the selection of cases (grey
paths) can impact an MR analysis between an exposure and disease progression as an outcome.
Associations are induced because SNP causes disease (via exposure), and thus conditioning on disease
induces an association between all variables causing disease. In a model not adjusting for exposure (e.g.,
relating SNP to progression), there is an association between SNP and the confounders, which biases the
SNP-progression association. Abbreviations: DAG, direct acyclic graph; MR, Mendelian randomization.
https://doi.org/10.1371/journal.pgen.1006944.g003
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2. Check for associations between the genetic variant and potential confounders in the study
sample (that are not present in overall population)—such associations might indicate that
both the genetic variant and confounders influence disease incidence [30].
3. If there are associations between a genetic variant and potential confounders of disease inci-
dence and progression, then adjusting for such confounders will mitigate the problem.
However, investigators should be aware that, as with any study of traditional risk factors,
unmeasured confounding and measurement error in assessed confounders will remain an
issue.
4. If certain parameters are known (such as the prevalence of disease and the effects of the
genetic and potential confounders on disease onset), then it is possible to estimate the
induced bias and so potentially correct for it using analytical formulae [28] or inverse prob-
ability weighting.
It is an important aside to note that, whilst disease incidence and diagnosis are the particu-
lar selection criteria of concern in the context of a progression study, any factor that relates to
the selection of study participants can result in collider bias [27]. Therefore, any study in
which the participants are not a random selection of the population can suffer from an induced
association between genetic variants and factors that are independent in the underlying
population.
Confounding with disease stage at baseline
Studies of progression should be carefully designed so that it is true “progression” that is the
outcome. Under some situations, disease detection (and hence the position of individuals
along the disease progression timeline at diagnosis) may be associated with other factors (e.g.,
smoking could be related to age at onset). For example, suppose that older people were more
likely to take part in a screening program because national screening programs often have a
lower age limit. Thus, older people with cancer would tend to have their cancer detected earlier
(by screening) and thus present with less advanced cancer, whereas younger people with can-
cer might present with symptomatic (more advanced) cancer. In a study of people with this
cancer, it would appear that age was a positive prognostic factor. However, if stage at study
entry was assessed, then the association between age and stage could be examined and con-
trolled for in the analysis. Ideally, the stage of disease at study entry should be independent of
the genetic variants. Collider bias with factors such as age might violate this—if age and genetic
variant both influence disease incidence, and age influences stage of disease at study entry,
then in a case-only study, the genetic variant would appear to be associated with age and hence
also with the stage of disease at study entry. In this example, this spurious correlation could be
removed by adjusting for age—however, in practice, all the factors influencing the risk of dis-
ease occurrence will not be known.
Measurement of progression
GWAS and MR typically use a single measure of either a continuous (e.g., blood pressure at
age 60) or a binary (e.g., occurrence of a myocardial infarction by age 60) outcome. In a study
of progression, the outcome may be more complex: time to cancer recurrence; survival time;
the accumulation of disability over a 20-year period; or recurrence-free survival time. For
these outcomes, a more sophisticated analysis may be required. When survival is the outcome
of interest, disease-specific as well as all-cause mortality should be investigated, and disease-
specific survival analysis will need to account for censoring (missing follow-up data) due to
death from other factors. Similarly, GWAS analysis methods for trajectories will be required
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for studies in which the outcome is a repeated quantitative measure (e.g., the progression of
disability in multiple sclerosis). We have developed a methodology for GWAS of trajectories
[31,32], and methods for MR in the context of survival analysis are available [33], but compu-
tational challenges remain, and further methodological development is much needed. In addi-
tion, to allow well-powered meta-analysis studies to be conducted, comparable measures of
progression will need to be available across data sets.
Availability of data
GWAS and MR of disease occurrence have had huge recent success, in no small part due to
the availability of very large data sets. In order for GWAS and MR of progression to see the
same success, there is a need for large-scale studies with both progression and genetic data.
One potential source of such data is randomized controlled trials, which will have detailed fol-
low-up of patients and often now collect DNA as a standard. Genome-wide genotyping of
such resources is an important first step. The generation of valuable progression data for
GWAS is likely to require large consortia collaboration (as has been the case for traditional
GWAS). Therefore, the standardization of progression measures across a number of studies is
also going to be important for this approach to reach its full potential.
If all of these issues are appropriately addressed, there is a huge opportunity for GWAS and
MR of disease progression to identify potential new treatments [34]. Platforms such as
MR-Base (www.MRbase.org) [35], which catalogs all available GWAS data for the simple
implementation of MR, will make it possible to screen a wide array of modifiable risk factors
and drug targets to prioritize those for evaluation as treatments for disease.
Supporting information
S1 Table. Mendelian randomization studies of progression. These were either known to us
or identified through PubMed search (progression OR prognosis OR survival OR mortality)
AND (Mendelian randomization OR Mendelian randomization, searched on 1 May 2017).
(XLSX)
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